@Myownmoney
On the negative, I beleive many are dissapointed in the current CEO with her disregard for informative reporting.
While the 'lumping' of many items into the Quarterly may have appeared lazy, I think you will find it may have more to do with how busy they are ? Maybe give the small team at Starpharma a little leeway on this ?
There are no current recruitment numbers identified for our trials over the last few reports which indicates the progress is slow. We all know it took 3 years for them to complete the Phase 1 Docetaxel trial and I expect a similar timeframe for the Phase 2.
I think you are making assumptions here that are not necessarily true ? They moved trials to London hospitals as there is access to more people with specific illnesses .... and the CEO stated at the AGM that the DEP Docetaxel phase 2 will be much quicker than the phase 1 trials; which IMO is already proving to be true ?.... I think you will also find that 'numbers' of patients and graphs etc are usually reserved for the final phases of the trial (happy to be corrected if this is not the case)
Add to My Watchlist
What is My Watchlist?
